Relmada Therapeutics, Inc. RLMD Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount.
The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount?
- Relmada Therapeutics, Inc. (RLMD) reported valuation allowance, deferred tax asset, increase (decrease), amount of $30.63M in Q4 2025.
- How has Relmada Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount changed year-over-year?
- Relmada Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount increased by 6.2% year-over-year, from $28.84M to $30.63M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount has grown at a 27.9% compound annual growth rate (CAGR), from $45.78M to $122.5M.
- What does valuation allowance, deferred tax asset, increase (decrease), amount mean?
- Represents the net change in the valuation allowance established against deferred tax assets. This adjustment reflects management's assessment of the likelihood that the company will generate sufficient future taxable income to realize the benefits of its tax assets.